[HTML][HTML] Interim effectiveness of updated 2023–2024 (monovalent XBB. 1.5) COVID-19 vaccines against COVID-19–associated emergency department and urgent …
J DeCuir - MMWR. Morbidity and Mortality Weekly Report, 2024 - cdc.gov
Abstract In September 2023, CDC's Advisory Committee on Immunization Practices
recommended updated 2023–2024 (monovalent XBB. 1.5) COVID-19 vaccination for all …
recommended updated 2023–2024 (monovalent XBB. 1.5) COVID-19 vaccination for all …
Effectiveness of Omicron XBB. 1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN. 1 variants, prospective cohort study, the Netherlands, October …
AJ Huiberts, CE Hoeve, B de Gier, J Cremer… - …, 2024 - eurosurveillance.org
We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB. 1.5 vaccination
against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB …
against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB …
Protecting the vulnerable: addressing the COVID-19 care needs of people with compromised immunity
RR Razonable - Frontiers in immunology, 2024 - frontiersin.org
While the general population regained a certain level of normalcy with the end of the global
health emergency, the risk of contracting COVID-19 with a severe outcome is still a major …
health emergency, the risk of contracting COVID-19 with a severe outcome is still a major …
[HTML][HTML] Neutralization of SARS-CoV-2 omicron subvariant BA. 2.87. 1
A new highly mutated Omicron subvariant BA. 2.87. 1 has recently been identified with over
30 amino acid mutations in the Spike protein compared with BA. 2, BA. 5, XBB. 1.5, and JN …
30 amino acid mutations in the Spike protein compared with BA. 2, BA. 5, XBB. 1.5, and JN …
COVID-19 Vaccination Strategies in the Endemic Period: Lessons from Influenza
Coronavirus disease 2019 (COVID-19) is a highly contagious zoonotic respiratory disease
with many similarities to influenza. Effective vaccines are available for both; however, rapid …
with many similarities to influenza. Effective vaccines are available for both; however, rapid …
Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA. 2.86 and descendant JN. 1 in Denmark: a …
IR Moustsen-Helms, P Bager, TG Larsen… - The Lancet Infectious …, 2024 - thelancet.com
Summary Background During the 2023 Danish COVID-19 vaccination campaign, an
updated monovalent mRNA vaccine targeting the SARS-CoV-2 omicron XBB. 1.5 subvariant …
updated monovalent mRNA vaccine targeting the SARS-CoV-2 omicron XBB. 1.5 subvariant …
[HTML][HTML] Broad immunogenicity to prior SARS-CoV-2 strains and JN. 1 variant elicited by XBB. 1.5 vaccination in nursing home residents
Background SARS-CoV-2 vaccination has reduced hospitalization and mortality for nursing
home residents (NHRs). However, emerging variants coupled with waning immunity …
home residents (NHRs). However, emerging variants coupled with waning immunity …
[HTML][HTML] Use of an Additional Updated 2023–2024 COVID-19 Vaccine Dose for Adults Aged≥ 65 Years: Recommendations of the Advisory Committee on …
L Panagiotakopoulos - MMWR. Morbidity and Mortality Weekly Report, 2024 - cdc.gov
COVID-19 remains an important public health threat, despite overall decreases in COVID-19–
related severe disease since the start of the COVID-19 pandemic. COVID-19–associated …
related severe disease since the start of the COVID-19 pandemic. COVID-19–associated …
Risks of SARS-CoV-2 JN. 1 infection and COVID-19 associated emergency-department (ED) visits/hospitalizations following updated boosters and prior infection: a …
C Chong, LE Wee, X Jin, M Zhang… - Clinical Infectious …, 2024 - academic.oup.com
Introduction Data on protection afforded by updated COVID-19 vaccines (bivalent/XBB 1.5
monovalent) against the emergent JN. 1 variant remains limited. Methods We conducted a …
monovalent) against the emergent JN. 1 variant remains limited. Methods We conducted a …
XBB. 1.5 mRNA COVID-19 vaccination and inpatient or emergency department visits among adults infected with SARS-CoV-2 JN. 1 and XBB-lineage variants
ME Levy, V Chilunda, PR Heaton, D McKeen… - medRxiv, 2024 - medrxiv.org
Within a multi-state viral genomic surveillance program, we conducted a case-control
analysis comparing prior receipt of XBB. 1.5-adapted mRNA vaccination between SARS …
analysis comparing prior receipt of XBB. 1.5-adapted mRNA vaccination between SARS …